新型非肽类口服生长抑素受体配体paltusotine的临床研究进展  

Clinical Research Progress of the Non-Peptide Oral Somatostatin Receptor Ligand Paltusotine

作　　者：刘宇珂 谭惠文[1,2] LIU Yuke;TAN Huiwen(Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,China;Center for Pituitary Adnomas and Related Diseases,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院内分泌代谢科,成都610041 [2]四川大学华西医院垂体瘤及相关疾病诊疗中心,成都610041

出　　处：《罕见病研究》2023年第3期414-419,共6页Journal of Rare Diseases

基　　金：四川省科技计划项目(2023YFS0259)。

摘　　要：生长抑素类似物相关制剂的研发是内分泌代谢领域的热点。第一代奥曲肽、兰瑞肽,第二代帕瑞肽已批准用于肢端肥大症等神经内分泌肿瘤的治疗。而生长抑素受体配体paltusotine作为一种可口服给药的新型非肽类小分子药物,可抑制生长激素和胰岛素样生长因子1的过度分泌。本文分析总结非肽类口服小分子生长抑素配体paltusotine的药物代谢动力学、药效动力学、临床疗效、耐受性和安全性等研究进展。The research and development of somatostatin analogues is a hot area in endocrinology and metabolism.The first generation octreotide,lanreotide and the second generation pareotide have been approved to be effective for the treatment of neuroendocrine tumors such as acromegaly.However,paltusotine,a somatostatin receptor ligand,is a novel non-peptide small molecule drug which can be administered orally and inhibits excessive secretion of growth hormone and insulin-like growth factor 1.This review summarizes the research progress of the pharmacokinetics,pharmacodynamics,clinical efficacy,telerability,and safety of paltusotine.

关 键 词：神经内分泌肿瘤 肢端肥大症 生长抑素受体配体 药物代谢动力学 药效动力学 

分 类 号：R584.11[医药卫生—内分泌] R736.4[医药卫生—内科学] R977[医药卫生—临床医学]